Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

• Main Authors: Flavia Manzo Margiotta (Author), Alessandra Michelucci (Author), Salvatore Panduri (Author), Laura Angeloni (Author), Cristian Fidanzi (Author), Giammarco Granieri (Author), Riccardo Morganti (Author), Marco Romanelli (Author), Valentina Dini (Author)
• Format: Book
• Published: Wiley, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Monoclonal antibodies (mAbs) directed against tumour necrosis factor alpha (TNF‐α) and interleukin (IL)‐17 and ‐23 represent the ultimate therapeutic strategy in treating psoriasis patients, but scientific literature still does not provide conclusive results regarding the possibl...